PURPOSE: AG3340 (prinomastat) is a nonpeptidic, small-molecular-weight, synthetic matrix metalloproteinase inhibitor (MMPI) with selective inhibitory action of MMP-2, MMP-9, MMP-3, and MT-MMP1. We evaluated AG3340 injected intravitreally to treat choroidal neovascularization in a laser induced rat CNV model. METHODS: In the pretreatment group, the drug was injected the same day after induction of choroidal neovascularization by diode laser. In the treatment group, the drug was injected 2 weeks after induction of choroidal neovascularization (CNV). Fluorescein and indocyanine green angiography were performed to evaluate CNV. ERG recordings and histology were performed to assess toxicity and the CNV lesions. RESULTS: When used at the time of CNV induction, 62.8% of lesions in control versus 22.8% of the laser lesions in treated eyes developed CNV (p < 0.0001). The invading fibrovascular complex was thicker in the control eyes than that in the treated eyes. No signs of toxicity were detected. When used to treat established CNV, the percentage of leakage in treated and control eyes were 54.1% and 58.9% respectively (p > 0.05). Prinomastat was effective when given at the time of induction of CNV in the rat model. Administration of prinomastat 2 weeks after laser induction did not show efficacy. CONCLUSION: Prinomastat was active in the earliest stages of experimental CNV. It might be best used in combination with photodynamic therapy to inhibit recurrence of CNV from temporarily closed new vessels.
PURPOSE:AG3340 (prinomastat) is a nonpeptidic, small-molecular-weight, synthetic matrix metalloproteinase inhibitor (MMPI) with selective inhibitory action of MMP-2, MMP-9, MMP-3, and MT-MMP1. We evaluated AG3340 injected intravitreally to treat choroidal neovascularization in a laser induced rat CNV model. METHODS: In the pretreatment group, the drug was injected the same day after induction of choroidal neovascularization by diode laser. In the treatment group, the drug was injected 2 weeks after induction of choroidal neovascularization (CNV). Fluorescein and indocyanine green angiography were performed to evaluate CNV. ERG recordings and histology were performed to assess toxicity and the CNV lesions. RESULTS: When used at the time of CNV induction, 62.8% of lesions in control versus 22.8% of the laser lesions in treated eyes developed CNV (p < 0.0001). The invading fibrovascular complex was thicker in the control eyes than that in the treated eyes. No signs of toxicity were detected. When used to treat established CNV, the percentage of leakage in treated and control eyes were 54.1% and 58.9% respectively (p > 0.05). Prinomastat was effective when given at the time of induction of CNV in the rat model. Administration of prinomastat 2 weeks after laser induction did not show efficacy. CONCLUSION:Prinomastat was active in the earliest stages of experimental CNV. It might be best used in combination with photodynamic therapy to inhibit recurrence of CNV from temporarily closed new vessels.
Authors: M S Seo; N Kwak; H Ozaki; H Yamada; N Okamoto; E Yamada; D Fabbro; F Hofmann; J M Wood; P A Campochiaro Journal: Am J Pathol Date: 1999-06 Impact factor: 4.307
Authors: A H Drummond; P Beckett; P D Brown; E A Bone; A H Davidson; W A Galloway; A J Gearing; P Huxley; D Laber; M McCourt; M Whittaker; L M Wood; A Wright Journal: Ann N Y Acad Sci Date: 1999-06-30 Impact factor: 5.691
Authors: D R Shalinsky; J Brekken; H Zou; C D McDermott; P Forsyth; D Edwards; S Margosiak; S Bender; G Truitt; A Wood; N M Varki; K Appelt Journal: Ann N Y Acad Sci Date: 1999-06-30 Impact factor: 5.691
Authors: Lingyun Cheng; Mitsuko Toyoguchi; David J Looney; Jeffery Lee; Marie C Davidson; William R Freeman Journal: Retina Date: 2005 Feb-Mar Impact factor: 4.256
Authors: Iryna A Falkenstein; Lingyun Cheng; Flossie Wong-Staal; Ajay M Tammewar; Erin C Barron; Gabriel A Silva; Qi-Xiang Li; Dehua Yu; Michelle Hysell; Guohong Liu; Ning Ke; James E Macdonald; William R Freeman Journal: Curr Eye Res Date: 2008-07 Impact factor: 2.424
Authors: Luis García-Onrubia; Fco Javier Valentín-Bravo; Rosa M Coco-Martin; Rogelio González-Sarmiento; J Carlos Pastor; Ricardo Usategui-Martín; Salvador Pastor-Idoate Journal: Int J Mol Sci Date: 2020-08-18 Impact factor: 5.923
Authors: Beata Osiecka; Kamil Jurczyszyn; Krzysztof Symonowicz; Andrzej Bronowicz; Paweł Ostasiewicz; Elzbieta Czapińska; Katarzyna Hotowy; Małgorzata Krzystek-Korpacka; Elzbieta Gebarowska; Ilona Izykowska; Piotr Dziegiel; Grzegorz Terlecki; Piotr Ziółkowski Journal: Cell Mol Biol Lett Date: 2010-09-17 Impact factor: 5.787
Authors: Sang Woong Moon; Yaoyao Sun; David Warther; Kristyn Huffman; William R Freeman; Michael J Sailor; Lingyun Cheng Journal: Drug Deliv Date: 2018-01-01 Impact factor: 6.419
Authors: Carrie M Louie; Gianluca Caridi; Vanda S Lopes; Francesco Brancati; Andreas Kispert; Madeline A Lancaster; Andrew M Schlossman; Edgar A Otto; Michael Leitges; Hermann-Josef Gröne; Irma Lopez; Harini V Gudiseva; John F O'Toole; Elena Vallespin; Radha Ayyagari; Carmen Ayuso; Frans P M Cremers; Anneke I den Hollander; Robert K Koenekoop; Bruno Dallapiccola; Gian Marco Ghiggeri; Friedhelm Hildebrandt; Enza Maria Valente; David S Williams; Joseph G Gleeson Journal: Nat Genet Date: 2010-01-17 Impact factor: 38.330
Authors: Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419